Liquidia Target of Unusually Large Options Trading (NASDAQ:LQDA)

Liquidia Corporation (NASDAQ:LQDA) saw unusually large options trading activity on Friday. Traders purchased 54,585 call options on the company. This is an increase of approximately 375% compared to the average volume of 11,501 call options.

Liquidia Trading Up 0.7%

LQDA traded up $0.26 on Friday, hitting $39.05. The company had a trading volume of 1,826,787 shares, compared to its average volume of 2,648,807. The company has a market cap of $3.40 billion, a PE ratio of -27.07, a PEG ratio of 0.68 and a beta of 0.48. Liquidia has a 12-month low of $11.26 and a 12-month high of $41.57. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. The business’s fifty day simple moving average is $32.68 and its 200 day simple moving average is $25.77.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. The business had revenue of $54.34 million for the quarter, compared to the consensus estimate of $18.86 million. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The firm’s revenue for the quarter was up 1106.7% on a year-over-year basis. Equities research analysts expect that Liquidia will post -1.51 EPS for the current year.

Insider Activity at Liquidia

In other Liquidia news, insider Scott Moomaw sold 20,533 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $768,550.19. Following the completion of the sale, the insider owned 154,514 shares of the company’s stock, valued at approximately $5,783,459.02. The trade was a 11.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jason Adair sold 13,548 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $507,101.64. Following the completion of the transaction, the insider directly owned 184,174 shares in the company, valued at $6,893,632.82. This trade represents a 6.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 323,354 shares of company stock valued at $11,046,731 in the last three months. Corporate insiders own 26.50% of the company’s stock.

Hedge Funds Weigh In On Liquidia

A number of large investors have recently made changes to their positions in LQDA. XTX Topco Ltd purchased a new position in Liquidia in the 2nd quarter worth about $1,485,000. Tyro Capital Management LLC purchased a new stake in Liquidia in the 2nd quarter valued at about $15,473,000. Diametric Capital LP grew its stake in Liquidia by 72.5% in the 2nd quarter. Diametric Capital LP now owns 148,601 shares of the company’s stock worth $1,852,000 after acquiring an additional 62,443 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Liquidia during the second quarter worth approximately $775,000. Finally, Pale Fire Capital SE bought a new stake in shares of Liquidia during the second quarter valued at approximately $1,068,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Zacks Research upgraded LQDA to a “strong-buy” and published a momentum-focused note highlighting recent revenue beats and upward price momentum — a catalyst for buys from momentum and growth-oriented investors. Zacks: Liquidia is a great momentum stock
• Neutral Sentiment: Laughing Water Capital mentioned Liquidia in its Q4 2025 investor letter — useful color on institutional interest/ownership but not a direct operational update. Institutional mentions can support sentiment over time. Laughing Water Capital update
• Neutral Sentiment: Liquidia presented at the J.P. Morgan Healthcare Conference (transcript released). Conference presentations can provide pipeline and commercial updates; investors will watch for any new guidance or milestone timing. J.P. Morgan Healthcare Conference transcript
• Negative Sentiment: Multiple insider sell filings surfaced this morning — filings show several officers/directors (including a CAO filing and a reported sale by Roger Jeffs) with aggregate reported proceeds of roughly $3.0M across the disclosed transactions. Insider selling can pressure sentiment if investors interpret it as reduced insider conviction, though context (planned sales, diversification, option exercises) matters. Roger Jeffs sells 66,610 shares CAO sells shares

Wall Street Analysts Forecast Growth

LQDA has been the subject of a number of research reports. Jefferies Financial Group upped their target price on shares of Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday. Raymond James Financial reiterated a “strong-buy” rating and issued a $47.00 price target on shares of Liquidia in a research note on Tuesday, November 4th. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a report on Wednesday, October 8th. Finally, Wall Street Zen raised Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, Liquidia has a consensus rating of “Moderate Buy” and a consensus target price of $39.67.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).